reports
Selvita S.A.: 1 director
A director at Selvita S.A. sold 20,000 shares at 67.900PLN and the significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society...
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting Clinical activity observed in 50% of evaluable patients with relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndromes (HR-MDS) treated with RVU120 monotherapy, including a complete response. Treatment continues to show a favorable safety profile with 50-70% target engagement achieved at a dose of 250 mg. The published clinical and non-clinical data strongly support RVU120’s Phase II development plans presented in October.A webinar discussing the data p...
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Ca...
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023 Translational data demonstrate synergistic activity of RVU120 and MEK inhibitors in hormone receptor-negative breast cancer KRAKOW, Poland, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE: RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced promising translational data on RVU120 in combination with MEK inhibitors at the San Antonio Breast Cancer Symposium (SABCS) 2023 being held ...
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Pro...
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update The total operating revenues amounted to $11.9M and increased by 42% compared to Q3 2022.Updated data from Phase Ib study of RVU120 in AML/HR-MDS to be presented at the upcoming American Society of Hematology (ASH) Annual Meeting in December. Preparations for executing Phase II clinical trials of RVU120 in AML and HR-MDS are in advanced stages.Ryvu’s PRMT5 program and synthetic lethality platform were highlighted with preclinical data recently presented at the 2023 AACR-NCI-EORTC International Confe...
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I...
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Solid Tumors and AML/HR-MDS, and Presents the Updated Development Plan for RVU120 KRAKOW, Poland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today updated clinical Phase I data from RVU120 Phase I/II study in patients with relapsed/refractory metastatic or advanced solid tumors, presented at the European Society for Medical ...
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthet...
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer modelsVirtual webinar on PRMT5 data and progress to be held on Monday, October 16 at 9.30 am CESTPreclinical efficacy data of MEN1703 (SEL24) in B-cell lymphomas to be presented by Ryvu’s partner Menarini KRAKOW, Poland, Oct. 04, 2023 (GLOBE NEWSW...
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provide...
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022.Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023.Preparation for the execution of Phase II clinical trials of RVU120 in AML and HR-MDS are in advanced stages.Warsaw Stock Exchange has included Ryvu stock in the mWIG40 index, which groups medium-sized companies.$14M in non-dilutive grant funding was secured from the Medical Research Agenc...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RV...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress Ongoing Phase 1b Dose-Escalation Study of Single-Agent Treatment with RVU120 in Patients with AML or High-Risk MDS Shows Clinical Benefit and Favorable Safety;Dose-Escalation Continues, Currently Enrolling at 175 mg;In vivo Data Show Synergistic Effects of RVU120 in Combination with Ruxolitinib in Myeloproliferative Neoplasms; KRAKOW, Poland, June 09, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company ...
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Pro...
Ryvu Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Updated Clinical Data from the Ongoing Phase Ib Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS and Preclinical Data from the Combination Study of RVU120 and Ruxolitinib in Myeloproliferative Neoplasms to be Presented at the upcoming 2023 EHA Congress;Anticipated commencement of three Ryvu-sponsored Phase II trials of RVU120 in solid tumors and AML/HR-MDS in 2H 2023;Updated in vivo data from the MTA-cooperative PRMT5 inhibitor program presented at AACR Annual Meeting 2023; KRA...
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 a...
Ryvu Therapeutics to Present Clinical and Preclinical Data on RVU120 at the 2023 European Hematology Association Congress Updated Clinical Data from the Ongoing Phase 1b Dose-Escalation Study of RVU120 in Patients with AML or High-Risk MDS Show Favorable Safety and Promising Signs of EfficacyPoster Presentation to Highlight Synergistic Effects of RVU120 in Combination with Ruxolitinib in Myeloproliferative Neoplasms KRAKOW, Poland, May 11, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therap...
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ...
Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update Signed a collaboration agreement with BioNTech to develop and commercialize immunomodulatory small molecule therapeutics; deal terms included €20M upfront payment, €20M equity investment in Ryvu, research funding, and downstream milestones and royalties;Successfully completed a Public Offering, raising gross proceeds of $56M;Planning to advance RVU120 to Phase II in the treatment of solid tumors and AML/HR-MDS in 2Q and 2H 2023 respectively; clinical updates at upcoming major medical ...
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Th...
Ryvu Therapeutics to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel and 12th Annual LifeSci Partners Corporate Access Event KRAKOW, Poland, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced that Pawel Przewiezlikowski, Chief Executive Officer of Ryvu Therapeutics, will participate in the Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel Discussion entitled ...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proc...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics [WSE:RVU], a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced the completion of its public offering of 4,764,674 Series J common shares (“Public Offering”). As a result of the Public Offering, Ryvu has obtained gross proceeds of PLN 250.3 million from institutional and individual investors as well as BioNTech and The Leukemia &...
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 a...
Ryvu Therapeutics Presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting RVU120 Demonstrates Single-Agent Activity with a Complete Response, 4 Blast Reductions, and 4 Erythroid and/or Platelet responses in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS);Preclinical Antitumor Activity of SEL24 (MEN1703) demonstrated in multiple myeloma (MM), Hodgkin’s lymphoma (HL), and diffuse large B-cell lymphoma (DLBCL) as well as in AML in combination with gilter...
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Pro...
Ryvu Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update Updated Phase Ib data on RVU120 in relapsed/refractory acute myeloid leukemia (r/r AML) or high-risk myelodysplastic syndrome (HR-MDS) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting Positive clinical data on RVU120 in advanced solid tumors and preclinical data on novel MTA-cooperative PRMT5 inhibitors presented at EORTC-NCI-AACR symposium KRAKOW, Poland, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE:RVU), a clinical-stage drug discovery and developmen...
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Tra...
Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting Six Presentations Highlight the Clinical and Preclinical Activity of RVU120 and SEL24 (MEN1703) RVU120 Demonstrates Single-Agent Activity with a Complete Response and Disease Stabilization in 10 Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS) Preclinical Models Show Potential for Clinical Efficacy of SEL24 (MEN1703) in multiple myeloma (MM), Hodgkin’s...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RV...
Ryvu Therapeutics Presents Updated Clinical and Preclinical Data on RVU120 at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium Updated data from Phase I/II dose-escalation study of RVU120 show four disease stabilizations in advanced solid tumor patients,RVU120 was well tolerated across all doses evaluated,Preclinical data demonstrate the potential of combination therapy with RVU120 and ADCC-promoting drugs,Novel MTA-cooperative PRMT5 inhibitors show preclinical antitumor efficacy and target engagement in MTAP-deleted cancers. KRAKOW, Poland, Oct. 26, 2022 (GLOBE NEW...
Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC...
Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium KRAKOW, Poland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced that it will present clinical data on RVU120 in relapsed/refractory metastatic or advanced solid tumors, preclinical data on RVU120 enhancing antibody-dependent cellular cytotoxicity and discovery, and optimization data on novel MTA-c...
EIB to Support Ryvu Therapeutics’ Discovery, Research and Development ...
EIB to Support Ryvu Therapeutics’ Discovery, Research and Development of New Cancer Treatments with €22 Million Ryvu Therapeutics, an innovative biotech company, receives EIB financing to accelerate the development of new therapies to treat severe blood cancers and solid tumours, including further clinical development of the flagship project RVU120. The funding is guaranteed by the European Fund for Strategic Investments, the financial pillar of the Investment Plan for Europe. WARSAW, Poland, Aug. 17, 2022 (GLOBE NEWSWIRE) -- The European Investment Bank (EIB) is providi...
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-...
Ryvu Therapeutics Announces Promotion of Hendrik Nogai and Vatnak Vat-Ho to the Management Board KRAKOW, Poland, July 26, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today announced the promotion of Hendrik Nogai, M.D., Chief Medical Officer, and Vatnak Vat-Ho, Chief Business Officer to its Management Board. “We are excited to promote Vatnak and Hendrik to the Management Board of Ryvu,” said Piotr Romanowski, President of Ryvu Therapeuti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.